卡伯戈林单疗法在GH和PRL共分泌的垂体腺瘤中
James M McNeil1,2, Nicholas C Candy3,4, Alistair K Jukes1,4
1Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Endocrine oncology (Bristol, England)
|January 14, 2026
概括
增长激素和前素共同分泌的垂体腺瘤 (GH和PRL-PAs) 可以有效地用卡伯戈林单疗法治疗. 这种方法表明,在这种罕见的瘤亚型的精选患者中,有望改善生化和结构.
科学领域:
- 内分泌学 在内分泌学.
- 神经瘤学神经瘤学
- 下垂体医学 下垂体医学
背景情况:
- 功能性垂体瘤或PitNETs通常分泌一种激素.
- 双激素高分泌,像GH和PRL-PA一样,带来了管理挑战.
- GH和PRL-PA是最常见的双重高分泌亚型,起源于PIT1系PitNETs.
研究的目的:
- 评估卡伯戈林单一治疗GH和PRL-PAs的疗效.
- 介绍一个用cabergoline治疗的巨型GH和PRL-PA的案例研究.
- 评估卡贝戈林在GH和PRL-PAs治疗武器库中的潜在作用.
主要方法:
- 一个患有巨型GH和PRL-PA的患者的病例报告.
- 预先使用卡伯戈林单一治疗.
- 评估生化,结构,眼科和临床反应.
主要成果:
- 患者实现了对卡伯戈林的完整生化 (GH和PRL) 和部分结构,眼科和临床反应.
- 以前的数据表明,在相关条件下,GH和结构性反应对卡伯戈林.
- 一些GH和PRL-PA可能会对卡贝戈林表现出"过度反应",包括快速降低激素和瘤缩.
结论:
- 卡伯戈林单疗是一种可行的治疗选择,用于选择GH和PRL-PAs.
- 这种方法可以带来显著的生化和结构改进.
- 需要进一步的研究来制定GH和PRL-PAs的具体治疗指南.
相关概念视频
Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Hormones of the Pituitary Gland
9.4K
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
9.4K
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.8K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.8K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
880
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
880


